What is Alx Oncology Holdings ?
, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 137.03M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 34,207 shares $8k | 0 |
| 6-9months | 213,214 shares $29k | 0 |
| 9-12months | 24,490 shares $6k | 13,184,713 shares $5.0M |